| | | Randomized Controlled Trial
Int J Infect Dis
. 2021 Feb;103:214-216.
doi: 10.1016/j.ijid.2020.11.191. Epub 2020 Dec 2.
A five-day course of ivermectin for the treatment of COVID-19 may reduce the duration of illness
Sabeena Ahmed 1, Mohammad Mahbubul Karim 1, Allen G Ross 1, Mohammad Sharif Hossain 1, John D Clemens 1, Mariya Kibtiya Sumiya 1, Ching Swe Phru 1, Mustafizur Rahman 1, Khalequ Zaman 1, Jyoti Somani 2, Rubina Yasmin 3, Mohammad Abul Hasnat 4, Ahmedul Kabir 5, Asma Binte Aziz 1, Wasif Ali Khan 6
Affiliations expand
PMID: 33278625 PMCID: PMC7709596 DOI: 10.1016/j.ijid.2020.11.191Free PMC article
Abstract
Ivermectin, a US Food and Drug Administration-approved anti-parasitic agent, was found to inhibit severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) replication in vitro. A randomized, double-blind, placebo-controlled trial was conducted to determine the rapidity of viral clearance and safety of ivermectin among adult SARS-CoV-2 patients. The trial included 72 hospitalized patients in Dhaka, Bangladesh, who were assigned to one of three groups: oral ivermectin alone (12 mg once daily for 5 days), oral ivermectin in combination with doxycycline (12 mg ivermectin single dose and 200 mg doxycycline on day 1, followed by 100 mg every 12 h for the next 4 days), and a placebo control group. Clinical symptoms of fever, cough, and sore throat were comparable among the three groups. Virological clearance was earlier in the 5-day ivermectin treatment arm when compared to the placebo group (9.7 days vs 12.7 days; p = 0.02), but this was not the case for the ivermectin + doxycycline arm (11.5 days; p = 0.27). There were no severe adverse drug events recorded in the study. A 5-day course of ivermectin was found to be safe and effective in treating adult patients with mild COVID-19. Larger trials will be needed to confirm these preliminary findings.
Keywords: Bangladesh; COVID-19; Doxycycline; Ivermectin; SARS-CoV-2.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
The authors declare that there are no known competing financial interests or personal relationships that could have appeared to influence the work described in this paper.
Figures
Figure 1
Cumulative viral recovery estimates in…
Similar articles
Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19): a structured summary of a study protocol for a randomized controlled trial.
Vallejos J, Zoni R, Bangher M, Villamandos S, Bobadilla A, Plano F, Campias C, Chaparro Campias E, Achinelli F, Guglielmone HA, Ojeda J, Medina F, Farizano Salazar D, Andino G, Ruiz Diaz NE, Kawerin P, Meza E, Dellamea S, Aquino A, Flores V, Martemucci CN, Vernengo MM, Martinez SM, Segovia JE, Aguirre MG.Trials. 2020 Nov 24;21(1):965. doi: 10.1186/s13063-020-04813-1.PMID: 33234158 Free PMC article. Clinical Trial.
Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A, Chua JV, Talwani R, Bentzen SM, Baddley J.Trials. 2020 Oct 28;21(1):897. doi: 10.1186/s13063-020-04819-9.PMID: 33115543 Free PMC article.
The SARS-CoV-2 Ivermectin Navarra-ISGlobal Trial (SAINT) to Evaluate the Potential of Ivermectin to Reduce COVID-19 Transmission in low risk, non-severe COVID-19 patients in the first 48 hours after symptoms onset: A structured summary of a study protocol for a randomized control pilot trial.
Chaccour C, Ruiz-Castillo P, Richardson MA, Moncunill G, Casellas A, Carmona-Torre F, Giráldez M, Mota JS, Yuste JR, Azanza JR, Fernández M, Reina G, Dobaño C, Brew J, Sadaba B, Hammann F, Rabinovich R.Trials. 2020 Jun 8;21(1):498. doi: 10.1186/s13063-020-04421-z.PMID: 32513289 Free PMC article.
Ivermectin: an award-winning drug with expected antiviral activity against COVID-19.
Formiga FR, Leblanc R, de Souza Rebouças J, Farias LP, de Oliveira RN, Pena L.J Control Release. 2021 Jan 10;329:758-761. doi: 10.1016/j.jconrel.2020.10.009. Epub 2020 Oct 7.PMID: 33038449 Free PMC article. Review.
The broad spectrum host-directed agent ivermectin as an antiviral for SARS-CoV-2 ?
Jans DA, Wagstaff KM.Biochem Biophys Res Commun. 2021 Jan 29;538:163-172. doi: 10.1016/j.bbrc.2020.10.042. Epub 2020 Oct 21.PMID: 33341233 Free PMC article. Review.
See all similar articles
Cited by 16 articles
Antiviral Effects of Ivermectin in COVID-19- Clinically Plausible.
Kumar Shukla DA, Misra DS.Int J Infect Dis. 2021 Jun 24:S1201-9712(21)00535-X. doi: 10.1016/j.ijid.2021.06.048. Online ahead of print.PMID: 34175482 Free PMC article. No abstract available.
Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: A randomized controlled study.
Abd-Elsalam S, Noor RA, Badawi R, Khalaf M, Esmail ES, Soliman S, Abd El Ghafar MS, Elbahnasawy M, Moustafa EF, Hassany SM, Medhat MA, Ramadan HK, Eldeen MAS, Alboraie M, Cordie A, Esmat G.J Med Virol. 2021 Jun 2:10.1002/jmv.27122. doi: 10.1002/jmv.27122. Online ahead of print.PMID: 34076901 Free PMC article.
Effects of a Single Dose of Ivermectin on Viral and Clinical Outcomes in Asymptomatic SARS-CoV-2 Infected Subjects: A Pilot Clinical Trial in Lebanon.
Samaha AA, Mouawia H, Fawaz M, Hassan H, Salami A, Bazzal AA, Saab HB, Al-Wakeel M, Alsaabi A, Chouman M, Moussawi MA, Ayoub H, Raad A, Hajjeh O, Eid AH, Raad H.Viruses. 2021 May 26;13(6):989. doi: 10.3390/v13060989.PMID: 34073401 Free PMC article. Clinical Trial.
Effects of Ivermectin in Patients With COVID-19: A Multicenter, Double-Blind, Randomized, Controlled Clinical Trial.
Shahbaznejad L, Davoudi A, Eslami G, Markowitz JS, Navaeifar MR, Hosseinzadeh F, Movahedi FS, Rezai MS.Clin Ther. 2021 May 6:S0149-2918(21)00201-0. doi: 10.1016/j.clinthera.2021.04.007. Online ahead of print.PMID: 34052007 Free PMC article.
Clinical Impact of the Early Use of Monoclonal Antibody LY-CoV555 (Bamlanivimab) on Mortality and Hospitalization Among Elderly Nursing Home Patients: A Multicenter Retrospective Study.
Alam MM, Mahmud S, Aggarwal S, Fathma S, Al Mahi N, Shibli MS, Haque SM, Mahmud S, Ahmed Z.Cureus. 2021 May 10;13(5):e14933. doi: 10.7759/cureus.14933.PMID: 33981518 Free PMC article.
See all "Cited by" articles
References
Alam M.T., Murshed R., Bhiuyan E., Saber S., Alam R., Robin R. A Case Series of 100 COVID-19 Positive Patients Treated with Combination of Ivermectin and Doxycycline. J Bangladesh Coll Physic Surg. 2020;38:10–15. doi: 10.3329/jbcps.v38i0.47512. - DOICaly L., Druce J.D., Catton M.G., Jans D.A., Wagstaff K.M. 2020. "The FDA-approved Drug Ivermectin inhibits the replication of SARS-CoV-2 in vitro. Antiviral Res, from ncbi.nlm.nih.gov (Caly et al. 2020), Apr 3. - PMC - PubMedCenters for Disease Control and Prevention . 2020. Interim Clinical Guidance for Management of Patients with Confirmed 2019 Novel Coronavirus (2019-nCoV) Infection, Updated March 7, 2020. [Available from: cdc.gov [accessed 17.11.2020]Chiu S.H., Lu A.Y. Metabolism and tissue residues. In: Campbell W.C., editor. Ivermectin and Abamectin. Springer-Verlag; New York, NY: 1989. pp. 131–143.Johns Hopkins University of Medicine COVID-19 . 2020. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University.https://coronavirus.jhu.edu/map.html (accessed 17.11.2020)
Show all 8 references
Publication types
Randomized Controlled Trial
MeSH terms
Adult
COVID-19 / drug therapy*
COVID-19 / virology
Double-Blind Method
Female
Humans
Ivermectin / adverse effects
Ivermectin / therapeutic use*
Male
Middle Aged
SARS-CoV-2*
Substances
Ivermectin
Supplementary concepts
COVID-19 drug treatment
Related information Cited in Books MedGen PubChem Compound (MeSH Keyword) |
|
